Coramitug is currently being investigated in the phase 3 CLEOPATTRA trial in approximately 1280 patients with ATTR-CM.

Improvements in some domains of cognitive function seen for patients with cancer receiving chemotherapy reporting cognitive problems.

Under the Bridge program, eligible beneficiaries can get Medicare coverage of GLP-1s for obesity for a $50 copay. Extending the short-term GLP-1 Bridge program is good news for eligible Medicare ...

No significant drug-related differences seen for clinical pain severity, thermal threshold or tolerance, general pain ...

The new weekly 120mg SC formulation, supported by TULIP-SC trial results, offers patients with moderate to severe SLE a self-administered alternative to monthly IV infusions.

Zanidatamab plus chemotherapy with or without tislelizumab significantly improves progression free survival in first-line ...

If approved, the neonatal Fc receptor blocker would become the first FDA-authorized therapy specifically indicated for patients with wAIHA.

A proprietary extended-release oral minoxidil, VDPHL01, shows superior efficacy and a consistent safety profile vs placebo for hair loss in men.

New long-term data from Study 304 confirms lumateperone 42mg significantly delays time to relapse in clinically stable patients with schizophrenia.

Lonvo-z is an in vivo CRISPR gene editing candidate that is designed to inactivate the kallikrein B1 gene, thereby permanently lowering kallikrein and bradykinin levels.

Treatment with three low-dose agents in single pill linked to lower incidence of recurrent stroke, major cardiovascular events in patients with hemorrhagic stroke ...

About one-third of children and adolescents use dietary supplements in the US, according to a study published online April 24 in Pediatrics Open Science. Brandy ...